Clinical trials: Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
- Trial name
- NCT04996758
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
RATIONALE: Inserting the gene for interleukin-2 into head and neck cancer cells may make the body build an immune response to kill the tumor cells.
- Trial name
- NCT00006033
- Testing
- gene therapy, interleukin-2 gene, methotrexate
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00049283
- Testing
- erlotinib hydrochloride, docetaxel, radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
NPC, HNSCC
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.
- Conditions
- NPC, HNSCC, Recurrence, Metastasis
- Trial name
- NCT06719479
- Testing
- IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabine
- Volunteers
- 60 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00507767
- Testing
- dasatinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Infection
Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Giving fluconazole may be effective in preventing or controlling mucositis caused by radiation therapy to the head and neck.
- Conditions
- Head and Neck Cancer, Infection, Oral Complications
- Trial name
- NCT00002533
- Testing
- fluconazole, radiation therapy
- Where
- United States
- Sponsor
- University of Miami
Nasopharyngeal Carcinoma
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line…
- Trial name
- NCT03906058
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Recurrent or Metastatic NPC
NPC - AXEL Study : Axitinib-Avelumab
Nasopharyngeal cancer (NPC) is the most common head and neck cancer in South China and South East Asia. Worldwide, there are 80,000 incident cases and 50,000 deaths annually.
- Trial name
- NCT04562441
- Testing
- Axitinib, Avelumab
- Where
- Hong Kong
- Volunteers
- 13 people
- Sponsor
- Chinese University of Hong Kong
Head and Neck Cancer
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer
RATIONALE: Studying gene mutations in samples of DNA from patients with head and neck cancer and a family history of cancer may help doctors learn more about the development of cancer in families.
- Trial name
- NCT00482872
- Testing
- gene expression analysis, mutation analysis, polymerase chain reaction
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Vanderbilt University Medical Center
Nasopharyngeal Cancer, Neoplasm Metastasis
Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions
Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.
- Trial name
- NCT03129412
- Testing
- radical radiotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Zhejiang Cancer Hospital
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Nasopharyngeal Cancinoma (NPC), Distant Metastasis
Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
An AI model was developed to predict the likelihood of distant metastasis in patients with nasopharyngeal cancer based on pathology slides and MRI scans of the primary tumor.
- Trial name
- NCT06831357
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Neurocognitive Impairment, Delirium
Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic
RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease.
- Conditions
- Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00533884
- Testing
- Assessment of therapy complications, Neurocognitive assessment, Quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Vanderbilt University Medical Center
Nasopharyngeal Carcinoma
Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to examine the efficacy of maintenance chemotherapy for the treatment of metastatic nasopharyngeal carcinoma. Participants will be randomized to 3 arms.
- Trial name
- NCT02944708
- Testing
- Conventional chemotherapy, Maintenance chemotherapy 1, Maintenance chemotherapy 2
- Where
- 14 sites in China, Singapore and 1 more
- Volunteers
- 384 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Nasopharyngeal Carcinoma
EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma
Epstein-Barr virus (EBV) infections is known to be a high-risk factor to induce cervical cancers. To date, EBV-related nasopharyngeal carcinoma (NPC) is still a major concern in east Asia, especially in China.
- Trial name
- NCT04509726
- Testing
- EBV-specific TCR-T cell with cytokine auto-secreting element
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Xinqiao Hospital of Chongqing
Nasopharyngeal Carcinoma
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
This is a randomized, open, multicenter phase II/III trial to compare the efficacy and safety of QL1706 and carrilizumab combined with gemcitabine and cisplatin in first-line treatment of recurrent or metastatic nasopharyngeal…
- Trial name
- NCT05576272
- Testing
- QL1706, Carrelizumab, Gemcitabine
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Head and Neck Cancer
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898664
- Testing
- cytogenetic analysis, gene expression analysis, mutation analysis
- Volunteers
- 74 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Nasopharyngeal Carcinoma (NPC)
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
In order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial.
- Trial name
- NCT07188584
- Testing
- Reduced-Target Radiotherapy, Conventional Full-Target Radiotherapy
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Ming-Yuan Chen